Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Akero Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Akero Therapeutics's regulatory disclosures and financial reporting.
Akero Therapeutics, Inc. (AKRO) Form 4 filing: Chief Technology Officer Scott A. Gangloff disclosed an automatic sale of 848 shares of common stock on 18 June 2025 at a weighted-average price of $54.84 per share. The transaction was executed under the company’s mandatory “sell-to-cover” policy to satisfy tax-withholding obligations triggered by the vesting of restricted stock units, meaning it was not a discretionary trade. After the sale, the executive continues to hold 23,452 shares directly.